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utoronto.ca (E.D. Mandelcorn), Rajeev.muni@gmail.com (R.H. Muni), mir.nabavi@utoronto.ca (M. Nabavi), peter.kertes@sunnybrook.ca (P.J. KeAbdullah Al-Kharashi a,b,⇑; Tural Galbinur a,c; Efrem D. Mandelcorn a,d; Rajeev H. Muni a,e; Mir Nabavi a; Peter J. Kertes a,fAbstractPurpose: To evaluate the efficacy of pre-operative intravitreal bevacizumab injection on the rate of postoperative vitreous hem-
orrhage in patients undergoing vitrectomy for complications of proliferative diabetic retinopathy.
Methods: Consecutive retrospective comparative cohort study. Forty eyes of 37 patients who received pre-operative intravitreal
bevacizumab 1.25 mg were compared to a similar group of 44 eyes of 44 patients who had undergone vitrectomy surgery prior to
the availability and widespread use of pre-operative intravitreal bevacizumab. The primary outcome measure was the incidence of
post-vitrectomy hemorrhage at one week after surgery. Secondary outcome measures included are postoperative vitreous hemor-
rhage at one month and changes in the best-corrected visual acuity (BCVA). For statistical analysis, the paired Student’s t-test and
Fisher’s exact test were used.
Results: Four out of 40 eyes (10%) pretreated with intravitreal bevacizumab vs. 12 of 44 eyes (27%) not pretreated with intravitreal
bevacizumab had a clinically significant postoperative vitreous hemorrhage at one week. The mean best-corrected visual acuity
(BCVA) in bevacizumab group improved from a mean of hand motions to a mean of 20/300 at 1 month (range: 20/25-light per-
ception; p < .001) and mean BCVA in the non-injected group improved from preoperative mean of hand motion to 20/200 at one
month follow-up (range: 20/25-no light perception; p < .001). In both groups, 4 patients (12%) needed repeat vitrectomy.
Conclusion: There is a trend to reduced incidence of early post-vitrectomy hemorrhage in patients undergoing vitrectomy for com-
plications of proliferative diabetic retinopathy that have been pre-treated with intravitreal bevacizumab 1 week prior to surgery.
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Postoperative vitreous hemorrhage after vitrectomy for
complications of diabetic retinopathy commonly occurs withan incidence of 12–63%.1–4 Patients with postoperative vitre-
ous hemorrhage suffer a delay in visual recovery while in
some patients, this can result in loss of vision and need for
reoperation. Although the source is often not identifiable,e:
al.com
a
x: +966
elcorn@
rtes).
218 A. Al-Kharashi et al.causes of early (or persistent) postoperative vitreous hemor-
rhage include dispersion of residual blood from the periph-
eral vitreous skirt or retinal surface, and oozing of blood
from dissected fibrovascular tissue or directly from the sclero-
tomies.2,5,6 Sources of late (or recurrent) postoperative vitre-
ous hemorrhage include fibrovascular proliferation from
sclerotomy sites and traction from residual fibrovascular
tissue.
In an effort to reduce the rate of post-operative vitreous
hemorrhage, systemic administration of anti-fibrinolytic
drugs,7,8 intravitreal thrombin,9 and sodium hyaluronate10
have been tried with relatively little success. Other possible
techniques include sclerotomy cryotherapy,11 and intravitreal
tamponade with silicone oil,12 or non-expandable gases (SF6
and C3F8
13,14).5–16 Bevacizumab (Avastin) is a recombinant
monoclonal antibody against vascular endothelial growth fac-
tor (VEGF) and has been used in the treatment of prolifera-
tive diabetic retinopathy (PDR) and other vascular
diseases.17,18 It can induce regression of retinal neovascular-
ization in diabetic patients and thereby facilitate fibrovascular
membrane dissection and reduce the amount of intraopera-
tive hemorrhage. It may also be used to expedite resolution
of non-clearing vitreous hemorrhage (VH).17 The IVB can also
be used as a preoperative adjunct in cases of vitrectomy for
complications of diabetes including tractional retinal detach-
ment (TRD) or non-clearing VH to decrease the risk of early
postoperative VH.19–22 We retrospectively evaluated our
cases of vitrectomy for proliferative diabetic retinopathy to
study the effect of pre-operative IVB injection on visual acuity
and on the rate of early post vitrectomy hemorrhage.Table 1. Baseline patient characteristics.
Bevacizumab
group
Untreated
group
p value
Number of eyes 40 44
Age (years) p>0.05
Mean 56.4 63.13
Range (27–83) (27–90)
Prior PRP 33 27 p = 0.520
Lens status
Phakic 27 32
Pseudophakic or
Aphakic
13 12 p = 0.6393
Use of insulin 26 25 p = 0.506
Macular TRD 5 9 p = 0.3895
PRP – Panretinal Photocoagulation.
TRD – Tractional Retinal Detachment.Materials and methods
This was a consecutive, retrospective, single-centered, sin-
gle surgeon (PJK) comparative cohort study that was
approved by our Institutional Research Ethics Board. The
charts of all diabetic patients with complicated PDR undergo-
ing vitrectomy between 2003 and 2009 were indentified and
reviewed. The routine use of pre-operative intravitreal beva-
cizumab began in the early 2006. The treated group was
drawn from consecutive patients undergoing vitrectomy sur-
gery for complications of proliferative diabetic retinopathy
and the control group was chosen from a similar number of
a pathology matched cohort undergoing surgery from 2003
to 2005. Eyes with complicated PDR undergoing surgery
for non-clearing VH or TRD involving or threatening the mac-
ula (with or without a rhegmatogenous component) were
included for analysis. Eyes undergoing vitrectomy for reasons
unrelated to complications of PDR, including chronic macular
edema, epiretinal membrane, and vitreomacular traction,
were excluded. Patient characteristics including age, sex,
visual acuity, history or pan-retinal photocoagulation (PRP),
prior intraocular surgery, use of insulin, macular TRD, and
lens status were documented from a review of the patient’s
chart. The use of endotamponade or the incidence of intra-
operative complications was also recorded.
Eyes in the bevacizumab (Avastin) group received an injec-
tion at a mean of 11 days after surgery (median = 8 days,
range: 1–53 days). All intravitreal injections were adminis-
tered in a standard fashion after obtaining informed consent.
Following administration of topical anesthetic drops, a lid
speculum was inserted and topical 2% xylocaine gel applied.A 10% povidone – iodine swab stick was then used to paint
the injection site. Bevacizumab (1.25 mg) in 0.05 mL in a pre-
filled syringe was injected using a 30-gauge needle 4 mm
posterior to the superotemporal corneoscleral limbus. No
injection-related complications were observed.
The surgical procedure was similar for the two groups. All
patients underwent a standard 20-gauge or 23-gauge 3-port
pars plana vitrectomy (PPV). Following sufficient clearance of
the vitreous hemorrhage to allow visualization of the poste-
rior pole when necessary, dissection of the pre-retinal
fibrovascular proliferation was carried out using a modified
en bloc technique. With elevation of the posterior hyaloid,
meticulous shaving of the vitreous base under a wide-angle
viewing system was performed with careful attention to
remove as much residual blood as possible. (Fill-in) panretinal
endolaser photocoagulation (PRP) was administered to any
area of previously untreated retina. Full attention was direc-
ted to relieving all traction. Hemostasis was maintained by
raising intraocular pressure, or by administering endolaser
or endodiathermy.
The primary outcome measure was the incidence of signif-
icant early post-vitrectomy hemorrhage at one week that pre-
vented visualization of the retina. Secondary outcome
measures included post-operative vitreous hemorrhage at
1 month, recurrent/persistent vitreous hemorrhage that
requires reoperation, and change in best-corrected visual
acuity (BCVA).
Descriptive statistics including numbers and percentages
of categorical variables, mean and standard deviation for
continuous variables were calculated for demographic and
clinical characteristics. Group comparisons were performed
using the chi-square test (Fisher’s exact test whenever indi-
cated). Snellen visual acuity was converted to logarithm of
maximum angle of resolution (LogMAR) units for purposes
of analysis.Results
Baseline characteristics
A total of 40 consecutive eyes pretreated with beva-
cizumab (Avastin) were compared to a similar group of 44
consecutive eyes of patients who had undergone vitrectomy
surgery prior to the availability and widespread use of beva-
cizumab. A comparison of the baseline characteristics of the
two groups is given in Table 1.
Use of bevacizumab in PDR 219There was no any statistically significant difference in
patient characteristics between the two groups.
Post-operative vitreous hemorrhage
Table 2 summarizes the incidence of early post-vitrectomy
vitreous hemorrhage and the number of patients who
required re-operation because of persistent vitreous
hemorrhage.
At one week post-operatively, 4 (10%) in the bevacizumab
group had VH whereas 12 (27.2%) in the control group had
VH (p = 0.054). Despite the trend of reduced risk in the treat-
ment group, the difference was not statistically significant. At
one month, 7 (17.5%) in the bevacizumab group and 9
(21.9%) in the control group had a significant VH
(p = 0.781); this difference was not statistically significant.
Three patients in the control group missed their second
month post-operative visit so their last observation was car-
ried forward.
Visual acuity
Results of the visual acuity and changes in visual acuity at
one month postvitrectomy are detailed in Table 3. In the
bevacizumab group, the mean BCVA at baseline was hand
motion (HM) and at one month was 20/300 (mean change
in LogMAR = 1.014) which is a statistically significant
improvement. In the control group, the mean BCVA at base-
line was HM and at one month was 20/200 (mean change in
LogMAR = 0.8790) which was also a statistically significant
improvement.
An independent 2-sample t-test comparing the change in
visual acuity at one month in the two groups determined that
there was no statistically significant difference between the
two groups (p = 0.594).
Discussion
Early post-vitrectomy hemorrhage can delay visual recov-
ery in patients who likely already have limited vision in their
contralateral eye and prevent any necessary post-operative
retinal treatment that may be needed including additional
laser treatment, with the risk of worsening foveal function
in the long-term.Table 2. Early postoperative VH.
Bevacizumab
group
Untreated
group
P-value
Number of eyes 40 44
VH at one week 4 (10%) 12 (27.2%) p = 0.0545
VH at one month 7 (17.5%) 9/41 (21.9%) p = 0.7813
Repeated vitrectomy 4 (10%) 4/41 (9.8%) p = 0.738
Table 3. Visual acuity at one month.
Bevacizumab
group
Untreated
group
p value
Preoperative HM HM p = 0.3049
One month postoperative 20/300 20/200 p = 0.594
Difference in LogMAR 1.014 0.8790The effects of bevacizumab on retinal neovascularization
secondary to diabetic retinopathy have been evaluated in a
number of studies.16,17 Avery et al. showed partial or com-
plete reduction of leakage from the foci of neovascularization
on fluorescein angiography within one week after intravitreal
injection of bevacizumab in 45 eyes with PDR.16 Similar stud-
ies19–23 have suggested that IVB may reduce the incidence of
intraoperative and postoperative vitreous hemorrhage in the
setting of diabetic vitrectomy by inducing regression of reti-
nal neovascularization which may facilitate fibrovascular
membrane dissection and consequently reduce intraopera-
tive hemorrhage. In addition, IVB may reduce postoperative
vascular oozing from neovascular stumps following operative
dissection of fibrovascular tissue. Since IVB is removed along
with the vitreous during vitrectomy surgery, there is likely lit-
tle benefit in pre-operative IVB in preventing post-operative
reproliferation that may occur weeks following vitrectomy
surgery. This may explain our observation that there was a
reduction in the incidence of early postoperative vitreous
hemorrhage in eyes pre-treated with IVB but no difference
in the incidence of delayed post-operative vitreous hemor-
rhage or a reduced need for reoperation.
Our study showed no statistically significant difference
between pretreated eyes and untreated eyes. This is similar
to reports by Lo et al.19 who compared 33 eyes pretreated
with bevacizumab and 104 untreated eyes and found no sta-
tistically significant difference between the two groups for
postoperative VH and final visual acuity with an overall inci-
dence of postvitrectomy VH of 13%. Romano et al.20 per-
formed a non-controlled prospective study on 32 eyes with
non-clearing VH resulting from active PDR, in which beva-
cizumab 2.5 mg was injected one week before vitrectomy.
The rate of VH recurrence was 3% at one week and one
month follow-up. In a prospective comparative study of 22
patients, Rizzo et al.21 reported that pre-operative beva-
cizumab reduces neovascularization and facilitates vitrec-
tomy. Mean BCVA improvement in the pretreated group at
the 6-month follow-up was better than that in the control
group although this difference did not reach up to the statis-
tical significance threshold. The authors also showed
decreased surgical time and less need for intraoperative tool
exchange in the treated group.
Some studies, on the other hand, demonstrate benefit to
pre-operative IVB. Ahmadieh et al.22 demonstrated in a ran-
domized, double-masked clinical trial of 68 eyes that IVB
injection before vitrectomy decreases the incidence of early
VH in high risk PDR. In spite of the significant difference
between the two groups, it can be argued that their patient
population is different, which might reflect different response
to pre-treatment with bevacizumab. In another prospective
randomized study conducted on 72 eyes, Di Lauro et al.
found a significant reduction in early postvitrectomy VH
(3 months follow-up) in eyes that IVB 7 and 20 days before
surgery.23 However, a significant number of eyes received sil-
icone oil tamponade and were not excluded before the sta-
tistical analysis was performed, which confounded the
occurrence of post-vitrectomy VH. Modarres also concluded
that IVB facilitates surgery despite the high number of sili-
cone oil tamponade in his series.24
The reported incidence of post-vitrectomy VH for compli-
cated PDR in recent studies23,24 is less than1,2 in studies that
were published more than 25 years ago. Although direct
220 A. Al-Kharashi et al.comparison of incidence rates among different studies is dif-
ficult, this likely reflects intervening advances in modern vit-
rectomy surgery. To minimize this bias, we strove to include
only those patients operated on in the same modern small
gauge vitrectomy era, that is to say those operated on in
the 3 years immediately before the availability and wide-
spread use of pre-operative IVB and those undergoing sur-
gery in the 3 years immediately following the introduction
of adjunctive IVB.
In the present study, both groups showed significant
improvement in BCVA but the difference in the improvement
of BCVA between the two groups was not significant
(p = 0.5942). This is in agreement with other studies.19–23
Modarres et al.24 showed significant differences between
the pre- and post-operative BCVA, in both the control and
treatment groups at last follow-up. In addition, the injected
group had better visual acuities than the control group.
One possible complication of IVB injection in PDR is
aggravation of fibrosis. In a report by Arevalo et al.,25 TRD
occurred in 11 of 211 eyes (5.2%) with severe PDR pretreated
with an intravitreal injection of bevacizumab more than a
week before the surgery. We did not encounter this compli-
cation in our series and believe that it can largely be avoided
by injecting patients not more than 1 week pre-operatively.
A major drawback in this comparative series is its retro-
spective nature, and the fact that the comparison groups
were non-randomized, and non-contemporaneous which
might generate bias and allow confounding factors to mask
the true effect of IVB injections in facilitating surgery and lim-
iting postvitrectomy hemorrhage and complications.
Post-vitrectomy VH is a significant complication following
vitrectomy for the treatment of PDR and remains a major
cause of morbidity. It not only delays visual recovery but
can lead to the need for re-operation further exposing the
patient to additional risk and anxiety and adding to the over-
all cost of care. The adjunctive use of the IVB 7 days before
vitrectomy for complicated PDR may decrease the incidence
of early post-vitrectomy VH.Funding
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